IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ant (s): Navid Malik, Ruth Duncan, Donald A. Tomalia and Roseita Esfand

Serial No.: 10/016,733

Group Art Unit: NA

Filed: October 29, 2001

Examiner: NA

For: A DENDRITIC-ANTINEOPLASTIC DRUG DELIVERY SYSTEM

EXPRESS MAILING LABEL NO. EL889202017 US I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL WITH SUFFICIENT POSTAGE IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS. WASHINGTON, DC 20231, ON:

> August 15, 2002 DATE OF DEPOSIT

Melissa A. Wagner

DATE OF SIGNATUR

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

## PETITION UNDER 37 CRF 1.47(a)

This is a Petition under 37 CFR 1.47(a) for an inventor who refuses to sign the Declaration and Power of Attorney [MPEP §409.3(a)]. The fee under §1.17(i) due for this Petition is hereby authorized to be charged to our Deposit Account No. 04-1512. If any other fee is required for this Petition it is also hereby authorized to be so charged.

The required Declaration and Power of Attorney forms for Navid Malik, Donald A. Tomalia and Roseita Esfand are provided with the Response to file Missing Parts.

Unfortunately, Ruth Duncan, one of the named inventors, has refused to sign a Declaration and Power of Attorney form. As evidence we enclose a Declaration by Karen L. Kimble, attorney for this application, with attaching documents as required

1

08/20/2002 SLUANG1 00000012 041512 10016733

82 10:122

130.00 CH

60,800B

RECEIVED

AUG 2 2 2002

OFFICE OF PETITIONS

under MPEP 409.3(d). Ruth Duncan refuses to sign these formal papers because she disagrees with the addition of the two added inventors (Tomalia and Esfand) for the new subject matter present in this application. We therefore submit that, pursuant to 37 CFR 1.47(a), Dr. Duncan's signature is not necessary to obtain.

Dr. Duncan's last known residential address is stated on the Declaration and Power of Attorney forms provided with the Response as: 143B Chiltern Court, London, NW1 1AX, United Kingdom; her last known business address is: Centre for Polymer Therapeutics, Welsh School of Pharmacy, Redwood Building, King Edward VII Avenue, Cardiff CF 3XF, United Kingdom.

Applicants request that the refusal of Dr. Ruth Duncaan to sign be acknowedged by the Office and this above-identified application held complete for the formal papers.

Respectfully submitted,

Karen L. Kimble

Registration No. 26,995 Phone: (989) 636-1687

P. O. Box 1967 Midland, MI 48641-1967

Enc.

Fee authorized in Petition

Dow letter to Dr. Duncan of March 11, 2002

Dow letter to Dr. Duncan of August 2, 2002

Dr. Julian C. Axe letter of August 9, 2002

60,800B -2-